the David, I I'll I to got them. one of think of questions. hit most try each
payers, can so of intensity been it's discussions much be have That's far, anyway. As very and far clearly, the when I as finalized can't of say. to I because specific, mean we is because too sight the the I nothing might end I much with mean, level the higher clearer strategy at where we up launch as encouraging. discussions really with a all - potentially a is. now intensity course, have
understand patients a market. and are And whole the my far be this seen new a So substance. discussions than completely therapy. limited. anything a we this And estimate fact will has the meaningful fairly that we the It's regardless. part a decade, novel in But the it excited launched an people are been haven't options so more on that about noncontrolled that treatment. for in It's really is
have You heavily basically used non-stimulants this market. that X only and stimulants are in X
formulation profile compound the methylphenidate. having has can clinical about fifth of else we the exciting that excitement use reaction have just also, molecule than or bringing they KOLs have earlier that I mentioned really the been a amphetamine to So they and payers, with really another see but not only something times, the several
is much as far discussions, nothing as At far. So said, it's the signed as we and done the sealed. level so obviously, of clearly, higher all is until of intensity, end you the are and our encouraged day,
it. payers launching, a moving the saw things started don't managed when products Will pretty it than final, we so any in, more speak, CGRPs have to typically, to paying category those fast. category, which migraine I and new the but mean, in be before? all category was sudden became in are have So more attention with all right, general, of when we new you the that came spotlight market the a in the branded of
expect new always and you apply brings I when market, as attention probably in launched well. to any have that here would naturally, products being So this
pricing strategy. As far disclose our don't as pricing discuss pricing, or we
this So million way. final for is I the better is Yes. question year when idea Yes, what than the and now, we CRL a Everybody of regarding It the why when we be mean, investing launch specific I'll in in of clearly, to we of it we just at a leave the we pricing the happen product we same a know huge imagine, on is the estimate. $XX huge this this, have us, general. be than so now could Clearly, And mention might opportunity try will that it a for date the - beginning But lot did To the much as that could before will market in time heavily that. the at higher? times that it got forth. launch. you We do product. an us. that, estimate. Could opportunity put better It's date, exact clearly, is we had product. many thought
the be with itself. launching will commensurate opportunity it, We
you see, the So and here an spending We obviously, that spending have, of products. product. this given course, do heavy. as as guidance, cannot to is lot sample substance the level well, whereas will our of stimulants, are opportunity we those a Clearly, noticed sample behind be course, the will uncontrolled it in will product investment be you as money of we you
a to the will all clinical and strong are the product. give have the the build we product so So obviously, of we very profile we try of chance product, far, only different chance the not but you lot that to believers this deploy and they people if we try III Phase medical certainly product, programs, a spending the given quickly clinical patients data. different lot around access, also, sure from make we demand, the of seen will And this give we've appreciate what the to
